Monocyte chemoattractant protein-1 (MCP-1) seems to be involved in the pathogenesis of multiple sclerosis (MS). We found that in unstimulated (PHA-) and PHA-stimulated (PHA+) peripheral blood mononuclear cells (PBMC), MCP-1 and TNFα levels are higher in stable untreated MS patients. Interferon gamma (IFNγ) is higher in relapsing patients in PHA- cultures and in stable patients in PHA+ cultures. Chronic IFNβ-1b treatment down-regulates TNFα, IFNγ and MCP-1 production except for TNFα in relapsing patients. IFNβ-1b, in vitro, increases MCP-1, TNFα and IFNγ spontaneous production in all patients. Multivariate analysis suggests that MCP-1 production is dependent from clinical status and not from TNFα and IFNγ production. Logistic regression analysis shows that MCP-1 production is significantly modified by treatment. Further studies are needed to clarify the role of MCP-1 in MS. © 2002 Elsevier Science B.V. All rights reserved.
Interferon β-1b modulates MCP-1 expression and production in relapsing-remitting multiple sclerosis / Iarlori, ; and Reale, C. a.; and De Luca, M. b.; and Di Iorio, G. a.; And, A. c.; Feliciani, C.; and Tulli, C. d.; and Conti, A. d.; and Gambi, P. b.; and Lugaresi, D. a.. - In: JOURNAL OF NEUROIMMUNOLOGY. - ISSN 0165-5728. - 123:1-2(2002), pp. 170-179. [10.1016/S0165-5728(01)00487-8]
Interferon β-1b modulates MCP-1 expression and production in relapsing-remitting multiple sclerosis
c. FelicianiWriting – Review & Editing
;
2002-01-01
Abstract
Monocyte chemoattractant protein-1 (MCP-1) seems to be involved in the pathogenesis of multiple sclerosis (MS). We found that in unstimulated (PHA-) and PHA-stimulated (PHA+) peripheral blood mononuclear cells (PBMC), MCP-1 and TNFα levels are higher in stable untreated MS patients. Interferon gamma (IFNγ) is higher in relapsing patients in PHA- cultures and in stable patients in PHA+ cultures. Chronic IFNβ-1b treatment down-regulates TNFα, IFNγ and MCP-1 production except for TNFα in relapsing patients. IFNβ-1b, in vitro, increases MCP-1, TNFα and IFNγ spontaneous production in all patients. Multivariate analysis suggests that MCP-1 production is dependent from clinical status and not from TNFα and IFNγ production. Logistic regression analysis shows that MCP-1 production is significantly modified by treatment. Further studies are needed to clarify the role of MCP-1 in MS. © 2002 Elsevier Science B.V. All rights reserved.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
